There is no way Better Therapeutics Inc. (BTTX) can keep these numbers up

Better Therapeutics Inc. (NASDAQ: BTTX) stock jumped 30.07% on Friday to $1.99 against a previous-day closing price of $1.53. With 45.39 million shares changed hands, the volume of the stock remained heavier than its average volume of 6.78 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.5600 whereas the lowest price it dropped to was $1.9100. The 52-week range on BTTX shows that it touched its highest point at $29.40 and its lowest point at $0.91 during that stretch. It currently has a 1-year price target of $17.00.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BTTX was up-trending over the past week, with a rise of 16.37%, but this was up by 17.75% over a month. Three-month performance surged to 99.00% while six-month performance fell -48.58%. The stock lost -79.96% in the past year, while it has lost -57.20% so far this year. A look at the trailing 12-month EPS for BTTX yields -2.15 with Next year EPS estimates of -4.24. For the next quarter, that number is -0.45. This implies an EPS growth rate of 37.00% for this year and -109.70% for next year.

Float and Shares Shorts:

At present, 23.41 million BTTX shares are outstanding with a float of 12.99 million shares on hand for trading. On Apr 28, 2022, short shares totaled 94160.0, which was 0.40% higher than short shares on Mar 30, 2022. In addition to Mr. David P. Perry M.B.A. as the firm’s Co-Founder & Exec. Chairman, Mr. Kevin J. Appelbaum serves as its Co-Founder, CEO & Director.

Institutional Ownership:

Through their ownership of 17.80% of BTTX’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 6.63% of BTTX, in contrast to 6.17% held by mutual funds. Shares owned by individuals account for 59.10%. As the largest shareholder in BTTX with 4.86% of the stake, Farallon Capital Management LLC holds 1,147,400 shares worth 1,147,400. A second-largest stockholder of BTTX, Sectoral Asset Management, Inc., holds 878,531 shares, controlling over 3.72% of the firm’s shares. The Vanguard Group, Inc. is the third largest shareholder in BTTX, holding 275,207 shares or 1.17% stake. With a 2.53% stake in BTTX, the Government Pension Fund – Global is the largest stakeholder. A total of 597,015 shares are owned by the mutual fund manager. The Victory RS Science & Technology F, which owns about 1.16% of BTTX stock, is the second-largest Mutual Fund holder. It holds 272,720 shares valued at 0.43 million. Vanguard Total Stock Market Index holds 1.03% of the stake in BTTX, owning 242,795 shares worth 0.38 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BTTX since 4 analysts follow the stock currently. There are 4 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With BTTX analysts setting a high price target of $21.00 and a low target of $15.00, the average target price over the next 12 months is $17.00. Based on these targets, BTTX could surge 955.28% to reach the target high and rise by 653.77% to reach the target low. Reaching the average price target will result in a growth of 754.27% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. BTTX will report FY 2022 earnings on 03/27/2023. Analysts have provided yearly estimates in a range of -$1.71 being high and -$2.06 being low. For BTTX, this leads to a yearly average estimate of -$1.89. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Better Therapeutics Inc. surprised analysts by -$0.03 when it reported -$0.41 EPS against a consensus estimate of -$0.39. The surprise factor in the prior quarter was -$0.25. Based on analyst estimates, the high estimate for the next quarter is -$0.42 and the low estimate is -$0.51. The average estimate for the next quarter is thus -$0.45.

Summary of Insider Activity:

Insiders traded BTTX stock several times over the past three months with 7 Buys and 0 Sells. In these transactions, 109,194 shares were bought while 0 shares were sold. The number of buy transactions has increased to 36 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 12,684,059 while 0 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *